Vol 65, No 1 (2014)
Original paper
Published online: 2014-02-19

open access

Page views 3070
Article views/downloads 2999
Get Citation

Connect on Social Media

Connect on Social Media

Proinsulin, adiponectin and hsCRP in reproductive age women with polycystic ovary syndrome (PCOS) — the effect of metformin treatment

Aleksandra Kruszyńska, Jadwiga Słowińska-Srzednicka, Wojciech Jeske, Wojciech Zgliczyński
DOI: 10.5603/EP.2014.0001
Endokrynol Pol 2014;65(1):2-10.


Introduction: Women with polycystic ovary syndrome (PCOS) often suffer from obesity and insulin resistance. The role of proinsulin, which is known to be an indicator of fertility outcomes in PCOS women, and that of adiponectin, in the pathogenesis of PCOS is not well elucidated. Our objective was to determine proinsulin, adiponectin, hsCRP and other hormonal and metabolic parameters in PCOS women before and after metformin treatment.

Material and methods: Two PCOS groups of patients of reproductive age (90 lean and 88 obese or overweight) with two control groups, adjusted for body mass index (BMI), were compared at baseline. 32 PCOS women were studied at baseline, after three and six months of metformin (1,000 mg/day) treatment. Clinical, anthropometric, biochemical and hormonal parameters were assessed.

Results: Proinsulin and hsCRP levels were the highest in obese PCOS women and were statistically different than in lean PCOS women (proinsulin: 11.4 v. 6.9 pmol/L; hsCRP 2.46 v. 0.47 mg/L, p < 0.01) and than in obese controls. Levels of adiponectin were dependant on BMI. Plasma proinsulin and androstenedione levels decreased after metformin treatment only in obese PCOS women.

Conclusions: PCOS, when accompanied by obesity, is associated with elevated proinsulin concentrations, which correlates with higher hsCRP and increased FAI. Proinsulin level decreases due to metformin treatment. Our results suggest that obese or overweight PCOS and lean PCOS are characterised by different hormonal and metabolic parameters and have a different response to metformin treatment. (Endokrynol Pol 2014; 65 (1): 2–10)